ALLO Stock – Knox Daily

Analysts Viewpoint

Allogene Therapeutics Inc’s filing revealed that its Officer Roberts Zachary acquired Company’s shares for reported $32014.0 on Feb 03 ’25.

Stock Earnings

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or

Analysts Viewpoint

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Analysts Viewpoint

In a filing, Allogene Therapeutics Inc revealed its Director MESSEMER DEBORAH M. unloaded Company’s shares for reported $19916.0 on Dec

Analysts Viewpoint

Allogene Therapeutics Inc’s recent filing unveils that its Director MESSEMER DEBORAH M. unloaded Company’s shares for reported $19916.0 on Dec

Featured

Allogene Therapeutics, Inc. (ALLO), a clinical-stage immuno-oncology company, has dipped 32.73% and hence, ALLO stock was trading at $16.40 when

Tag: ALLO Stock